fluvoxamine and tryptamine

fluvoxamine has been researched along with tryptamine* in 2 studies

Other Studies

2 other study(ies) available for fluvoxamine and tryptamine

ArticleYear
HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies.
    Journal of pharmaceutical and biomedical analysis, 2007, Mar-12, Volume: 43, Issue:4

    A simple, specific and sensitive high-performance liquid chromatographic (HPLC) method has been developed for the assay of fluvoxamine in human plasma and urine. The method was based on reaction of fluvoxamine with 1,2-naphthoquinone-4-sulphonic acid sodium salt (NQS) forming orange colored product. The fluvoxamine-NQ derivative was separated by isocratic reversed-phase HPLC and detected at 450 nm. The chromatographic conditions were as follows: Phenomenex C(18) (250 mm x 4.6 mm i.d., 5 microm) column, mobile phase consisting of acetonitrile/water (80:20 v/v) at a flow rate of 1 ml/min. Tryptamine was selected as an internal standard. The assay was linear over the concentration range of 5-145 and 2-100 ng/ml for plasma and urine, respectively. The limits of detection (LOD) were 1.4 and 1 ng/ml for plasma and urine estimation at a signal-to-noise (S/N) ratio of 3. The limits of quantification (LOQ) were 5 and 2 ng/ml for plasma and urine, respectively. The extraction recoveries were found to be 96.66+/-0.69 and 96.73+/-2.17% for plasma and urine, respectively. The intra-day and inter-day standard deviations (S.D.) were less than 1. The method indicated good performance in terms of specificity, linearity, detection and quantification limits, precision and accuracy. This assay was demonstrated to be applicable for clinical pharmacokinetic studies.

    Topics: Chromatography, High Pressure Liquid; Coloring Agents; Fluvoxamine; Humans; Molecular Structure; Naphthoquinones; Sensitivity and Specificity; Spectrophotometry; Tryptamines

2007
Fluvoxamine, a new antidepressant drug, fails to show antiserotonin activity.
    European journal of pharmacology, 1982, Jul-09, Volume: 81, Issue:2

    Fluvoxamine, (E)-5-methoxy-4'-(trifluoromethyl)valerophenone O-2(2-aminoethyl)oxime, a new antidepressant drug inhibiting serotonin (5-HT) uptake, was studied in rats and mice in order to check whether it has any central anti-5-HT activity, as do some tricyclic antidepressants, e.g. amitriptyline and doxepin. Fluvoxamine did not influence either the 5-hydroxytryptophan-induced head twitch response in mice or the tryptamine convulsions in rats. In the hind limb flexor reflex of the spinal rat the stimulation induced by fenfluramine was inhibited, that induced by LSD was not changed. Fluvoxamine also antagonized the hyperthermia (at ambient temperature of 28 degrees C), induced in rats by fenfluramine or p-chloroamphetamine. The hyperthermia caused by m-chlorophenylpiperazine was not inhibited. Fluvoxamine did not antagonize the 5-HT pressor effect in pithed rats. It has no effect on the immobility time in the behavioural despair test in rats. The results indicate that fluvoxamine fails to show anti-5-HT activity.

    Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Body Temperature; Fluvoxamine; Male; Mice; Oximes; Rats; Rats, Inbred Strains; Reflex; Serotonin Antagonists; Spinal Cord; Tryptamines

1982